Patent litigation reform could accelerate US biosimilar market entry, which lags behind the EU due to protracted legal processes. Biosimilar manufacturers face options like pre-clearance, "at-risk" ...

An expert Q&A on the US Patent and Trademark Office’s (USPTO’s) 2025 guidance memoranda addressing the Patent Trial and Appeal Board’s (PTAB’s) approach to discretionary denials of inter partes review ...

“The factors driving perception that patents have lost their value are certainly relevant and have had a substantial impact on patent litigation [but] none of these factors, alone or in combination, ...

“A tailored strategy can help maximize the advantages of China’s administrative patent infringement procedure while minimizing uncertainties.” There are two distinct procedures available to parties ...